Rhea-AI Summary
Omega Therapeutics, Inc. (Nasdaq: OMGA) announced financial results for Q1 2024, highlighting progress in MYCHELANGELO™ I trial dose escalation, new preclinical data in NSCLC, and upcoming ASGCT presentation. The company reported cash balance of $60.0 million, reduced R&D expenses, and net loss decrease. Omega is a biotech company developing programmable epigenomic mRNA medicines with a diverse pipeline.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-11.63%
Tags
-
Rhea-AI Summary
Summary not available.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.09%
Tags
-
Rhea-AI Summary
Summary not available.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.27%
Tags
Rhea-AI Summary
Summary not available.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.82%
Tags
-
Rhea-AI Summary
Summary not available.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
5.47%
Tags
-
Rhea-AI Summary
Summary not available.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-8.08%
Tags
Rhea-AI Summary
Summary not available.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.23%
Tags
-
Rhea-AI Summary
Summary not available.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.5%
Tags
-
Rhea-AI Summary
Summary not available.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.16%
Tags
Rhea-AI Summary
Summary not available.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-5.06%
Tags
FAQ
What is the current stock price of Omega Therapeutics (OMGA)?
Omega Therapeutics (OMGA) last closed at $0.1426.
What is the market cap of Omega Therapeutics (OMGA)?
The market cap of Omega Therapeutics (OMGA) is approximately $7.9M.